$LLY, Price correction?

٩ سبتمبر ٢٠٢٣

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

Positive:

• Yields high return on invested capital
  
• Has raised its dividend for 8 consecutive years
  
• 13 analysts have revised their earnings upwards for the upcoming period
  
• Prominent player in the Pharmaceuticals industry
  
• Cash flows can sufficiently cover interest payments
  
• High return over the last year
  
• An analyst from Morgan Stanley maintained Eli Lilly (NYSE: LLY) at 'overweight' with a price target of $640.00 from a prior price target of $617.00.
  

Negative:

• Trading at a high earnings multiple
  
• Corporate insiders Sold shares worth 21.3B in the past 3 months
  
• Hedge funds Sold 789.5K shares in the past quarter
  

Very strong bullish trend, it is expecting a price correction after this stock should follow